MET and clear cell sarcoma: On the other hand, crizotinib, an ALK inhibitor which has been investigated to rhabodmyosarcoma with ALK expression above, is known as inhibiting other targets such as MET, and showed some clinical responses to clear cell sarcomas overexpressing MET [109].